InsightfulValue
← Home

Takeda Pharmaceutical
Takeda Pharmaceutical

Pharma / Pharmaceuticals, Healthcare


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

More reviews (1)
Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company headquartered in Japan. The company was founded in 1781 and has a rich history of over 200 years of continuous operation.
Takeda is one of the world's largest pharmaceutical companies, with a focus on developing and delivering innovative medicines to patients in more than 80 countries and regions around the world. The company's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neurology, and rare diseases.
With a commitment to improving the health and well-being of people worldwide, Takeda strives to develop safe and effective medicines to treat a wide range of diseases and conditions. In addition to its core therapeutic areas, the company also has a growing portfolio in vaccines and consumer healthcare.
Takeda's corporate philosophy, "Takeda-ism," emphasizes its dedication to ethical and responsible business practices, as well as its commitment to patients, employees, and the global community.
Today, Takeda has a team of more than 49,000 employees worldwide, and its research and development efforts are led by a diverse network of scientists, researchers, and physicians who collaborate globally to drive innovation and advancement in the pharmaceutical industry.
What is special about the company?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIHNldmVy YWwgYXNwZW N0cyB0aGF0 IG1ha2UgVG FrZWRhIFBo YXJtYWNldX RpY2FsIHN0 YW5kIG91dC BhcyBhIGNv bXBhbnk6PG JyPjEuIExv bmcgSGlzdG 9yeTogVGFr ZWRhIFBoYX JtYWNldXRp Y2FsIHdhcy Bmb3VuZGVk IGluIDE3OD EsIG1ha2lu ZyBpdCBvbm Ugb2YgdGhl IG9sZGVzdC Bjb21wYW5p ZXMgaW4gSm FwYW4gYW5k IHRoZSB3b3 JsZC4gVGhp cyBsb25nIG hpc3Rvcnkg aGFzIGFsbG 93ZWQgdGhl IGNvbXBhbn kgdG8gZ2Fp biBleHRlbn NpdmUga25v d2xlZGdlIG FuZCBleHBl cmllbmNlIG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 48YnI+Mi4g SW50ZXJuYX Rpb25hbCBQ cmVzZW5jZT ogVGFrZWRh IGhhcyBhIH N0cm9uZyBn bG9iYWwgcH Jlc2VuY2Us IHdpdGggb3 BlcmF0aW9u cyBpbiBvdm VyIDgwIGNv dW50cmllcy BhbmQgcmVn aW9ucyB3b3 JsZHdpZGUu IEl0IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiBlbWVy Z2luZyBtYX JrZXRzLCBl c3BlY2lhbG x5IGluIEFz aWEsIHdoZX JlIHRoZSBj b21wYW55IG hhcyBhIGxl YWRpbmcgcG 9zaXRpb24g aW4gdGhlIH BoYXJtYWNl dXRpY2FsIG luZHVzdHJ5 Ljxicj4zLi BEaXZlcnNl IFBvcnRmb2 xpbzogVGFr ZWRhIGhhcy BhIGRpdmVy c2UgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzLCBjb3Zl cmluZyBhIH dpZGUgcmFu Z2Ugb2YgdG hlcmFwZXV0 aWMgYXJlYX MsIGluY2x1 ZGluZyBvbm NvbG9neSwg Z2FzdHJvZW 50ZXJvbG9n eSwgbmV1cm 9zY2llbmNl LCByYXJlIG Rpc2Vhc2Vz LCBhbmQgdm FjY2luZXMu IFRoaXMgZG l2ZXJzaWZp Y2F0aW9uIG hlbHBzIHRo ZSBjb21wYW 55IG1pdGln YXRlIHJpc2 tzIGFuZCBt YWludGFpbi BhIHN0YWJs ZSByZXZlbn VlIHN0cmVh bS48YnI+NC 4gSW5ub3Zh dGlvbjogVG FrZWRhIGhh cyBhIHN0cm 9uZyBmb2N1 cyBvbiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQg KFImRCksIH dpdGggYSBz aWduaWZpY2 FudCBpbnZl c3RtZW50IG luIGN1dHRp bmctZWRnZS B0ZWNobm9s b2d5IGFuZC Bjb2xsYWJv cmF0aW9ucy B3aXRoIGV4 dGVybmFsIH BhcnRuZXJz LiBUaGUgY2 9tcGFueSBh bHNvIGhhcy BhIHJvYnVz dCBwaXBlbG luZSBvZiBw b3RlbnRpYW wgbmV3IHRy ZWF0bWVudH MsIGVuc3Vy aW5nIGl0cy Bsb25nLXRl cm0gZ3Jvd3 RoLjxicj41 LiBDb3Jwb3 JhdGUgU29j aWFsIFJlc3 BvbnNpYmls aXR5OiBUYW tlZGEgaXMg Y29tbWl0dG VkIHRvIGNv cnBvcmF0ZS ByZXNwb25z aWJpbGl0eS BhbmQgaGFz IHNldCBhbW JpdGlvdXMg Z29hbHMgdG 8gcmVkdWNl IGl0cyBlbn Zpcm9ubWVu dGFsIGltcG FjdCBhbmQg aW1wcm92ZS BhY2Nlc3Mg dG8gaGVhbH RoY2FyZSBn bG9iYWxseS 4gVGhlIGNv bXBhbnkgYW xzbyBoYXMg dmFyaW91cy Bwcm9ncmFt cyBpbiBwbG FjZSB0byBz dXBwb3J0IG NvbW11bml0 aWVzIGFuZC Bwcm9tb3Rl IGRpdmVyc2 l0eSBhbmQg aW5jbHVzaW 9uLjxicj42 LiBWYWx1ZX MtRHJpdmVu IEN1bHR1cm U6IFRha2Vk YSdzIGNvcm UgdmFsdWVz LCBzdWNoIG FzICJpbnRl Z3JpdHksIG ZhaXJuZXNz LCBhbmQgaG 9uZXN0eSIg YW5kICJwdX R0aW5nIHRo ZSBwYXRpZW 50IGZpcnN0 LCIgYXJlIG RlZXBseSBp bmdyYWluZW QgaW4gaXRz IGNvcnBvcm F0ZSBjdWx0 dXJlLiBUaG lzIHN0cm9u ZyBldGhpY2 FsIGZvdW5k YXRpb24gZ3 VpZGVzIHRo ZSBjb21wYW 55J3MgZGVj aXNpb24tbW FraW5nIGFu ZCBkcml2ZX MgaXRzIGNv bW1pdG1lbn QgdG8gbWFr aW5nIGEgcG 9zaXRpdmUg aW1wYWN0IG luIHRoZSB3 b3JsZC48Yn I+SW4gY29u Y2x1c2lvbi wgVGFrZWRh IFBoYXJtYW NldXRpY2Fs J3MgbG9uZy BoaXN0b3J5 LCBnbG9iYW wgcHJlc2Vu Y2UsIGRpdm Vyc2UgcG9y dGZvbGlvLC Bmb2N1cyBv biBpbm5vdm F0aW9uLCBj b21taXRtZW 50IHRvIHNv Y2lhbCByZX Nwb25zaWJp bGl0eSwgYW 5kIHZhbHVl cy1kcml2ZW 4gY3VsdHVy ZSBhbGwgbW FrZSBpdCBh IHVuaXF1ZS BhbmQgc3Vj Y2Vzc2Z1bC Bjb21wYW55 IGluIHRoZS BwaGFybWFj ZXV0aWNhbC BpbmR1c3Ry eS4=
What the company's business model?
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

VGhlIFRha2 VkYSBQaGFy bWFjZXV0aW NhbCBjb21w YW55J3MgYn VzaW5lc3Mg bW9kZWwgaX MgYmFzZWQg b24gcmVzZW FyY2hpbmcs IGRldmVsb3 BpbmcsIG1h bnVmYWN0dX JpbmcsIGFu ZCBtYXJrZX RpbmcgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMuIF RoZSBjb21w YW55IGZvY3 VzZXMgb24g dGhlIGZvbG xvd2luZyBr ZXkgYXJlYX M6PGJyPjEu IFJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudDogVGFr ZWRhIGludm VzdHMgaGVh dmlseSBpbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgdG8gZG lzY292ZXIg YW5kIGRldm Vsb3AgbmV3 IG1lZGljaW 5lcyBmb3Ig ZGlzZWFzZX Mgd2l0aCBo aWdoIHVubW V0IG1lZGlj YWwgbmVlZH MuPGJyPjIu IE1hbnVmYW N0dXJpbmc6 IFRha2VkYS BoYXMgYSBn bG9iYWwgbm V0d29yayBv ZiBtYW51Zm FjdHVyaW5n IGZhY2lsaX RpZXMgdG8g cHJvZHVjZS BpdHMgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMgYX QgaGlnaCBx dWFsaXR5IG FuZCBlZmZp Y2llbmN5Lj xicj4zLiBN YXJrZXRpbm cgYW5kIHNh bGVzOiBUYW tlZGEgbWFy a2V0cyBhbm Qgc2VsbHMg aXRzIHByb2 R1Y3RzIHRv IGhlYWx0aG NhcmUgcHJv ZmVzc2lvbm FscyBhbmQg cGF0aWVudH MgZ2xvYmFs bHkgdGhyb3 VnaCB2YXJp b3VzIGNoYW 5uZWxzLCBp bmNsdWRpbm cgc2FsZXMg cmVwcmVzZW 50YXRpdmVz LCBkaWdpdG FsIG1hcmtl dGluZywgYW 5kIHBhcnRu ZXJzaGlwcy B3aXRoIGhl YWx0aGNhcm Ugb3JnYW5p emF0aW9ucy 48YnI+NC4g RGl2ZXJzaW ZpY2F0aW9u OiBUYWtlZG EgaGFzIGEg ZGl2ZXJzZS Bwb3J0Zm9s aW8gb2YgcG hhcm1hY2V1 dGljYWwgcH JvZHVjdHMs IHJhbmdpbm cgZnJvbSBw cmVzY3JpcH Rpb24gbWVk aWNpbmVzIH RvIG92ZXIt dGhlLWNvdW 50ZXIgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUgcH JvZHVjdHMu PGJyPjUuIE dlb2dyYXBo aWMgZXhwYW 5zaW9uOiBU YWtlZGEgb3 BlcmF0ZXMg aW4gb3Zlci A4MCBjb3Vu dHJpZXMgYW 5kIGNvbnRp bnVlcyB0by BleHBhbmQg aXRzIHByZX NlbmNlIGlu IGVtZXJnaW 5nIG1hcmtl dHMsIHBhcn RpY3VsYXJs eSBpbiBBc2 lhIGFuZCBM YXRpbiBBbW VyaWNhLjxi cj42LiBTdH JhdGVnaWMg cGFydG5lcn NoaXBzIGFu ZCBhY3F1aX NpdGlvbnM6 IFRha2VkYS Bjb2xsYWJv cmF0ZXMgd2 l0aCBvdGhl ciBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgYW5k IHJlc2Vhcm NoIGluc3Rp dHV0aW9ucy B0byBkZXZl bG9wIG5ldy B0cmVhdG1l bnRzIGFuZC B0ZWNobm9s b2dpZXMuIF RoZSBjb21w YW55IGFsc2 8gYWNxdWly ZXMgb3RoZX IgY29tcGFu aWVzIHRvIG V4cGFuZCBp dHMgcHJvZH VjdCBwb3J0 Zm9saW8gYW 5kIGdlb2dy YXBoaWMgcm VhY2guPGJy PjcuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog VGFrZWRhIG ZvY3VzZXMg b24gdW5kZX JzdGFuZGlu ZyBwYXRpZW 50cycgbmVl ZHMgYW5kIH dvcmtzIHRv IGRldmVsb3 AgdHJlYXRt ZW50cyB0aG F0IG1lZXQg dGhvc2Ugbm VlZHMuIFRo ZSBjb21wYW 55IGFsc28g aW52ZXN0cy BpbiBwYXRp ZW50IGVkdW NhdGlvbiBh bmQgYWNjZX NzIHByb2dy YW1zIHRvIG 1ha2UgdHJl YXRtZW50cy Btb3JlIGFj Y2Vzc2libG UgdG8gdGhv c2UgaW4gbm VlZC48YnI+ T3ZlcmFsbC wgVGFrZWRh J3MgYnVzaW 5lc3MgbW9k ZWwgaXMgY2 VudGVyZWQg b24gaW5ub3 ZhdGlvbiwg c3RyYXRlZ2 ljIHBhcnRu ZXJzaGlwcy wgYW5kIGEg cGF0aWVudC 1jZW50cmlj IGFwcHJvYW NoIHRvIGJy aW5nIGxpZm UtY2hhbmdp bmcgbWVkaW NpbmVzIHRv IHBlb3BsZS Bhcm91bmQg dGhlIHdvcm xkLg==
Interesting facts about the company
Takeda Pharmaceutical

πŸ“ˆ Want to read more about Takeda Pharmaceutical?

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvVz hVeWd5Y2dj ekVBMVhsRE 5nNjIud2Vi cCIgYWx0PS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgVGFrZWRh IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+GkyBE aXNjb3Zlci A8aT4iVGhl IENoZWNrbG lzdCBWYWx1 ZSBJbnZlc3 RvciDigJQg QSBTbWFydG VyIFdheSB0 byBQaWNrIF N0b2NrcyI8 L2k+IOKAlC BmcmVlIGVC b29rIQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 L3A+CgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID EycHg7IGZv bnQtc2l6ZT ogMTNweDsg Y29sb3I6IC M0NDQ7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIFNp Z24gdXAgbm 93IGFuZCBn ZXQgb3VyIG ZyZWUgZUJv b2sgCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8Yj5UaG UgQ2hlY2ts aXN0IFZhbH VlIEludmVz dG9yIOKAlC BBIFNtYXJ0 ZXIgV2F5IH RvIFBpY2sg U3RvY2tzPC 9iPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgLS 0+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwhLS 0KICAgICAg ICAgICAgIC AgICAgICAg ICAgPGRpdi BzdHlsZT0n bWFyZ2luLX RvcDogMTZw eDsgZm9udC 1zaXplOiAx NHB4OyBjb2 xvcjogIzQ0 NDsgZm9udC 1mYW1pbHk6 IC1hcHBsZS 1zeXN0ZW0s IEJsaW5rTW FjU3lzdGVt Rm9udCwgU2 Vnb2UgVUks IFJvYm90by wgSGVsdmV0 aWNhIE5ldW UsIHNhbnMt c2VyaWY7IG xpbmUtaGVp Z2h0OiAxLj Y7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIEhhdmUg eW91IGhlYX JkIGFib3V0 IG91ciBzaG 9ydCA8c3Ry b25nIHN0eW xlPSdmb250 LXdlaWdodD ogNjAwOyc+ RGFpbHkgVm lkZW8gTmV3 c2xldHRlcj wvc3Ryb25n Pj8KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IDxhIGhyZW Y9J2h0dHBz Oi8vd3d3Lm luc2lnaHRm dWx2YWx1ZS 5jb20vbmV3 c2xldHRlci 5waHAnIHRh cmdldD0nX2 JsYW5rJyBz dHlsZT0nY2 9sb3I6ICMw MDdCRkY7IH RleHQtZGVj b3JhdGlvbj ogbm9uZTsg Zm9udC13ZW lnaHQ6IDUw MDsgbWFyZ2 luLWxlZnQ6 IDZweDsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIEZpbmQg b3V0IG1vcm UKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICAKICAgIC AgICAKICAg ICAgICA8c3 BhbiBjbGFz cz0nYmx1cn JlZC10ZXh0 Jz4KICAgIC AgICAgICAg TVM0Z1ZHRn JaVyBSaElG Qm9ZWEp0IF lXTmxkWFJw WTIgRnNJR2 x6SUdFZyBT bUZ3WVc1bG MyIFVnYlhW c2RHbHUgWV hScGIyNWhi QyBCd2FHRn liV0ZqIFpY VjBhV05oYk MgQmpiMjF3 WVc1NSBMQ0 JvWldGa2NY IFZoY25SbG NtVmsgSUds dUlGUnZhMy BsdkxDQktZ WEJoIGJpNG dTWFFnYVgg TWdiMjVsSU c5bSBJSFJv WlNCc1lYIE puWlhOMElI Qm8gWVhKdF lXTmxkWCBS cFkyRnNJR0 52IGJYQmhi bWxsY3kgQn BiaUIwYUdV ZyBkMjl5Yk dRZ1luIGtn Y21WMlpXNT EgWlM0OFlu SStNaSA0Z1 ZHaGxJR052 IGJYQmhibm tnZDIgRnpJ R1p2ZFc1ay BaV1FnYVc0 Z01UIGM0TV NCaWVTQkQg YUc5aVpXa2 dWRyBGclpX UmhJRWtnIF lXNWtJSGRo Y3kgQnBibW wwYVdGcyBi SGtnWTJGc2 JHIFZrSUZS aGEyVmsgWV NCRGFHOWla VyBrZ1VHaG hjbTFoIFky VjFkR2xqWV cgd2dVMmh2 Y0M0ZyBTWF FnZDJGeklH IEVnYzIxaG JHd2cgY0do aGNtMWhZMy BrZ2FXNGdS Rzl6IGFHOX RZV05vYVMg d2dUM05oYT JFcyBJRXBo Y0dGdUxqIH hpY2o0ekxp QlUgWVd0bF pHRWdVRyBo aGNtMWhZMl YxIGRHbGpZ V3dnWW0gVm pZVzFsSUdF ZyBjSFZpYk dsaklHIE52 YlhCaGJua2 cgYVc0Z01U azBPUyBCaG JtUWdkMkZ6 IElHeHBjM1 JsWkMgQnZi aUIwYUdVZy BWRzlyZVc4 Z1UzIFJ2WT JzZ1JYaGog YUdGdVoyVX VQRyBKeVBq UXVJRlJoIG EyVmtZZUtB bVggTWdiV0 ZwYmlCbSBi Mk4xY3lCcG N5IEJ5WlhO bFlYSmogYU NCaGJtUWda RyBWMlpXeH ZjRzFsIGJu UWdhVzRnZE cgaGxJR1pw Wld4ayBjeU J2WmlCdmJt IE52Ykc5bm VTd2cgWjJG emRISnZaVy A1MFpYSnZi RzluIGVTd2 dZVzVrSUcg TmxiblJ5WV d3ZyBibVZ5 ZG05MWN5IE J6ZVhOMFpX MGcgWkdsem IzSmtaWCBK ekxpQkpkQ0 JoIGJITnZJ SEJ5YjIgUj FZMlZ6SUha aCBZMk5wYm 1WeklHIEZ1 WkNCdmRtVn kgTFhSb1pT MWpiMyBWdW RHVnlJRzFs IFpHbGpZWF JwYjIgNXpM anhpY2o0MS BMaUJVYUdV Z1kyIDl0Y0 dGdWVTQm8g WVhNZ1lTQm 5iRyA5aVlX d2djSEpsIG MyVnVZMlVz SUggZHBkR2 dnYjNCbCBj bUYwYVc5dW N5IEJwYmlC dmRtVnkgSU Rnd0lHTnZk VyA1MGNtbG xjeUJoIGJt UWdjbVZuYV cgOXVjeXdn YVc1aiBiSF ZrYVc1bklI IFJvWlNCVm JtbDAgWldR Z1UzUmhkRy BWekxDQkZk WEp2IGNHVX NJR0Z1WkMg QkJjMmxoTG p4aSBjajQy TGlCVVlXIH RsWkdFZ2FH RnogSUdFZ2 MzUnliMiA1 bklHTnZiVz FwIGRHMWxi blFnZEcgOG djM1Z6ZEdG cCBibUZpYV d4cGRIIGtn WVc1a0lIZG ggY3lCc2FY TjBaVyBRZ2 FXNGdkR2hs IElFUnZkeU JLYjIgNWxj eUJUZFhOMC BZV2x1WVdK cGJHIGwwZV NCSmJtUnAg WTJWeklHWn ZjaSBBeE1T QmpiMjV6IF pXTjFkR2wy WlMgQjVaV0 Z5Y3k0OCBZ bkkrTnk0Z1 NXIDRnTWpB d09Dd2cgVk dGclpXUmhJ RyBGamNYVn BjbVZrIElF MXBiR3hsYm 0gNXBkVzBn VUdoaCBjbT FoWTJWMWRH IGxqWVd4ek xDQmggSUd4 bFlXUnBibS BjZ1ltbHZj R2hoIGNtMW hZMlYxZEcg bGpZV3dnWT I5dCBjR0Z1 ZVNCbWIyIE 4xYzJWa0lH OXUgSUhSb1 pTQmtaWCBa bGJHOXdiV1 Z1IGRDQnZa aUJ2Ym0gTn ZiRzluZVNC MCBjbVZoZE cxbGJuIFJ6 TGp4aWNqND QgTGlCVVlX dGxaRyBFZ2 FYTWdhVzUy IGIyeDJaV1 FnYVcgNGdk bUZ5YVc5MS BjeUJ3WVhK MGJtIFZ5Yz JocGNITWcg WVc1a0lHTn ZiRyB4aFlt OXlZWFJwIG IyNXpJSGRw ZEcgZ2diM1 JvWlhJZyBj R2hoY20xaF kyIFYxZEds allXd2cgWT I5dGNHRnVh VyBWekxDQm hZMkZrIFpX MXBZeUJwYm 4gTjBhWFIx ZEdsdiBibk 1zSUdGdVpD IEJ5WlhObF lYSmogYUNC dmNtZGhibS BsNllYUnBi MjV6IExqeG ljajQ1TGkg QlVhR1VnWT I5dCBjR0Z1 ZVNCaGJIIE 52SUdoaGN5 QmggSUhOMG NtOXVaeSBC bWIyTjFjeU J2IGJpQnBi bTV2ZG0gRj BhVzl1SUdG dSBaQ0JwYm 5abGMzIFJ6 SUdobFlYWn AgYkhrZ2FX NGdjbSBWel pXRnlZMmdn IFlXNWtJR1 JsZG0gVnNi M0J0Wlc1MC BMaUJKYmlB eU1EIEl3TE NCcGRDQnog Y0dWdWRDQn ZkbSBWeUlD UTBJR0pwIG JHeHBiMjRn YjIgNGdVaV pFTGp4aSBj ajR4TUM0Z1 ZHIEZyWldS aElHaGggY3 lCaElISnBZ MiBnZ2FHbH pkRzl5IGVT QmhibVFnYU cgRnpJSEJz WVhsbCBaQ0 JoSUhOcFoy IDVwWm1sal lXNTAgSUhK dmJHVWdhVy A0Z2RHaGxJ R1JsIGRtVn NiM0J0Wlcg NTBJRzltSU hSbyBaU0J3 YUdGeWJXIE ZqWlhWMGFX TmggYkNCcG JtUjFjMyBS eWVTQnBiaU JLIFlYQmhi aTRnU1ggUW dhR0Z6SUdK bCBaVzRnY2 1WamIyIGR1 YVhwbFpDQj MgYVhSb0lH NTFiVyBWeW IzVnpJR0Yz IFlYSmtjeU JoYm0gUWdh Rzl1YjNKei BJRzkyWlhJ Z2RHIGhsSU hsbFlYSnog TGp4aWNqNH hNUyA0Z1ZH RnJaV1JoIE lHaGhjeUJo SUcgTnZjbk J2Y21GMCBa U0J3YUdsc2 IzIE52Y0do NUlHTmggYk d4bFpDQlVZ VyB0bFpHRX RhWE50IExD QjNhR2xqYU MgQmxiWEJv WVhOcCBlbV Z6SUhSb1pT IEJqYjIxd1 lXNTUgNG9D WmN5QmpiMi AxdGFYUnRa VzUwIElIUn ZJSEJoZEcg bGxiblJ6TE NCbCBiWEJz YjNsbFpYIE 1zSUdGdVpD QnogYjJOcF pYUjVMaiB4 aWNqNHhNaT RnIFZHaGxJ R052YlggQm hibmtnYUdG eiBJR1poWT JWa0lHIE5v WVd4c1pXNW 4gWlhNZ2FX NGdjbSBWal pXNTBJSGxs IFlYSnpMQ0 JwYm0gTnNk V1JwYm1jZy BjR0YwWlc1 MElHIFY0Y0 dseVlYUnAg YjI1eklHRn VaQyBCc1pX ZGhiQ0JwIG MzTjFaWE1n Y20gVm5ZWE prYVc1biBJ SE52YldVZ2 IyIFlnYVhS eklHMWwgWk dsallYUnBi MiA1ekxpQk liM2RsIGRt VnlMQ0JwZE MgQmpiMjUw YVc1MSBaWE 1nZEc4Z1lt IFVnWVNCdF lXcHYgY2lC d2JHRjVaWC BJZ2FXNGdk R2hsIElHZH NiMkpoYkMg QndhR0Z5Yl dGaiBaWFYw YVdOaGJDIE J0WVhKclpY UXUgUEdKeV BqRXpMaSBC SmJpQXlNRE l4IExDQlVZ V3RsWkcgRW dZVzV1YjNW dSBZMlZrSU dsMGN5IEJw Ym5SbGJuUn AgYjI0Z2RH OGdZbSBWam IyMWxJR0Vn IFoyeHZZbU ZzSUcgeGxZ V1JsY2lCcC BiaUJ5WVhK bElHIFJwYz JWaGMyVnog SUhkcGRHZ2 dZUyBCbmIy RnNJSFJ2IE lHeGhkVzVq YUMgQXpNQ0 J5WVhKbCBJ R1JwYzJWaG MyIFVnZEdo bGNtRncgYV dWeklHSjVJ RCBJd016QX VQR0p5IFBq RTBMaUJVWV cgdGxaR0Vn YVhNZyBZV3 h6YnlCcmJt IDkzYmlCbW IzSWcgYVhS eklITjBjbS A5dVp5Qmpi M0p3IGIzSm hkR1VnWTMg VnNkSFZ5Wl NCaCBibVFn YUdGeklHIE psWlc0Z2Nt VmogYjJkdW FYcGxaQyBC aGN5QnZibV VnIGIyWWdk R2hsSUggZH ZjbXhrNG9D WiBjeUJ0Yj NOMElHIEZr YldseVpXUW cgWTI5dGNH RnVhVyBWek lHSjVJRVp2 IGNuUjFibV VnVFcgRm5Z WHBwYm1VZy BabTl5SURF d0lHIE52Ym 5ObFkzVjAg YVhabElIbG xZWCBKekxq eGljajR4IE 5TNGdTVzRn WVcgUmthWF JwYjI0ZyBk RzhnY0doaG NtIDFoWTJW MWRHbGogWV d4ekxDQlVZ VyB0bFpHRW dhWE1nIFlX eHpieUJwYm 4gWnZiSFps WkNCcCBiaU IyWVhKcGIz IFZ6SUc5MG FHVnkgSUdK MWMybHVaWC BOelpYTXNJ R2x1IFkyeD FaR2x1Wnkg Qm1iMjlrSU hCeSBiMlIx WTNSekxDIE JvWldGc2RH Z2cgWVc1a0 lHSmxZWCBW MGVTQnpkWE J3IGJHVnRa VzUwY3kgd2 dZVzVrSUcx bCBaR2xqWV d3Z1pHIFYy YVdObGN5ND 0KICAgICAg ICA8L3NwYW 4+CiAgICAg ICAgCiAgIC AgICAg
See Company Q&A
Takeda Pharmaceutical

πŸ“Š Get full analytics about Takeda Pharmaceutical

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal